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ABSTRACT
Background HIV self- testing (HIVST) requires 
linkage to post- test services to maximise its benefits. 
We evaluated effect of supply- side incentivisation 
on linkage following community- based HIVST and 
evaluated time- trends in facility- based antiretroviral 
therapy (ART) initiations.
Methods From August 2016 to August 2017 community- 
based distributors (CBDs) in 38 rural Zimbabwean 
communities distributed HIVST door- to- door in 19–25 day 
campaigns. Communities were allocated (1:1) using 
constrained randomisation to either one- off US$50 
remuneration per CBD (non- incentive arm), or US$50 
plus US$0.20 incentive per client visiting mobile- outreach 
services (conditional- incentive arm). The primary 
outcome, assessed by population survey 6 weeks later, 
was self- reported uptake of any clinic service, analysed 
with random- effects logistic regression. Separately, non- 
randomised difference- in- differences in monthly ART 
initiations were analysed for three time periods (6 months 
baseline; HIVST campaign; 3 months after) at public clinics 
with (40 clinics) and without (124 clinics) HIVST distribution 
in catchment area.
Findings A total of 445 conditional- incentive CBDs 
distributed 39 205 HIVST kits (mean/CBD: 88; 95% CI: 85 
to 92) and 447 non- incentive CBDs distributed 41 173 kits 
(mean/CBD: 93; 95% CI: 89 to 96). Survey participation 
was 7146/8566 (83.4%), with 3593 (50.3%) reporting 
self- testing including 1305 (18.3%) previously untested 
individuals. Use of clinic services post- HIVST was similar 
in conditional- incentive (1062/3698, 28.7%) and non- 
incentive (1075/3448, 31.2%) arms (adjusted risk ratio 
(aRR) 0.94, 95% CI: 0.86 to 1.03). Confirmatory testing by 
newly diagnosed/untreated HIVST+clients was, however, 
higher (conditional- incentive: 25/33, 75.8% vs non- 
incentive: 20/40, 50.0%: aRR: 1.59, 95% CI: 1.05 to 2.39). 
In total, 12 808 ART initiations occurred, with no baseline or 
postcampaign differences between initiation rates in HIVST 
versus non- HIVST clinics, but initiation rates increased 
from 7.31 to 9.59 initiations per month in HIVST clinics 
during distribution, aRR: 1.27, 95% CI 1.17 to 1.39.
Key questions
What is already known?
 ► HIV self- testing increases uptake of HIV testing using 
a range of delivery models.
 ► Linking to post- test services will increase benefits 
and cost effectiveness of HIV self- testing.
 ► Demand- side incentives increase linkage to post- 
test services but the role of supply- side incentives 
is less clear.
 ► We investigated whether supply- side incentives 
increase linkage to post- test services during 
community- based distribution of HIV self- test kits.
What are the new findings?
 ► Community- based, door- to- door distribution of HIV 
self- test kits improved testing coverage.
 ► Supply- side incentives for test kit distributors did not 
increase post- test service uptake.
 ► In a post- hoc analysis supply- side incentives for HIV 
self- test kit distributors increased uptake of confir-
matory testing among newly diagnosed HIV positive 
self- testers.
 ► Community- based, door- to- door distribution of HIV 
self- tests was associated with a 27% increase in 
antiretroviral therapy initiations at nearby health 
facilities.
What do the new findings imply?
 ► Community- based, door- to- door delivery of HIV self- 
test kits is feasible and scalable.
 ► Future research should aim to optimise the nature 
and size of incentives to increase uptake and linkage 
while weighing the benefits and costs.
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Conclusions Community- based HIVST campaigns achieved high testing 
uptake, temporally associated with increased demand for ART. Small 
supply- side incentives did not affect general clinic usage but may have 
increased confirmatory testing for newly diagnosed HIVST positive 
participants.
Trial registration number PACTR201607001701788.
INTRODUCTION
HIV testing services (HTS) are a key entry point for HIV 
prevention and treatment services. Despite major invest-
ment in HTS, an estimated 21% of people living with HIV 
(PLHIV) globally were unaware of their status in 2018.1 
HIV self- testing (HIVST), whereby an individual uses 
a rapid diagnostic test to collect their own sample (oral 
or blood), performs the test and interprets the result, is 
recommended by WHO.2 It is highly acceptable,3–7 safe 
and can be highly accurate.8–10 Adding HIVST to clinic- 
based HTS can increase coverage and frequency of HIV 
testing, including among those less well- served by more 
traditional HTS approaches, such as rural populations, 
men, young people and key populations (sex workers, 
men having sex with men, transgender people, prisoners 
and people who inject drugs).11–15 Projections suggest that 
4.6% of all 360 million HIV tests used each year globally will 
be self- tests by 2020, with higher percentages of 10%–35% 
in Kenya, Malawi, Zambia, Zimbabwe and South Africa.16
A reactive (positive) HIVST result needs confirmatory 
testing to provide an HIV- positive diagnosis followed by 
prompt linkage into HIV care.2 A negative HIVST result 
(which does not need confirmatory testing) provides an 
opportunity for HIV prevention, such as voluntary medical 
male circumcision (VMMC), pre- exposure prophylaxis 
and use of condoms. Ensuring linkage following HIVST 
is essential for maximising health outcomes and cost- 
effectiveness.17 Evidence to date has been limited, but 
trials suggest that supportive linkage strategies are needed, 
including home- based antiretroviral therapy (ART) initia-
tion18 and financial incentives provided to HIVST clients,19 
among other strategies.20 However, the role of financial 
incentives for providers (‘supply- side’ incentives) has 
not previously been investigated for effectiveness on the 
later stages of the HIV care cascade (linkage and reten-
tion) (The HIV care cascade is the series of stages an HIV 
positive person goes through from HIV testing through to 
treatment initiation and viral suppression).21
The formative work that we conducted in non- trial 
sites showed that community- based HIVST is an accept-
able and feasible model for providing HIVST.4 Here 
we report results from a cluster- randomised trial inves-
tigating conditional supply- side incentives given to 
lay community- based distributors (CBDs) to promote 
linkage to services following HIVST.
METHODS
Population and setting
We conducted the study in Zimbabwe, a country with 
an HIV prevalence of 14.1%.12 At the time of the study, 
Zimbabwe had already adopted HIVST into policy 
although self- tests were not yet widely available. Eight 
districts took part: Buhera, Bulilima, Chivi, Gutu, Gweru, 
Masvingo, Mazowe and Mberengwa, where the study unit 
was a ward (subdistrict administrative unit). We used 
administrative maps of the districts (online supplemental 
appendix 1) to select 44 out of a possible 254 wards 
with geographic separation. The number of districts was 
informed by the sample size: we continued to include 
new districts until we reached 44 eligible wards.
Starting with a randomly selected ward at the boundary 
of the district, we systematically worked through each 
map to select additional wards while ensuring that each 
was at least 15 km away from its nearest neighbour/s. The 
districts were chosen because of the presence of Popu-
lation Services International (PSI) outreach clinics that 
deliver services, including standard HIV testing services, 
screening for TB, diabetes and hypertension, family plan-
ning and VMMC (Implementation of HIVST distribution 
was carried out by Unitaid/PSI as part of the Self Testing 
AfRica Initiative22). Within each district, there were 
public sector primary health clinics providing a range 
of services including provider- delivered HIV testing and 
treatment services. PSI worked closely with these facili-
ties to prepare them to receive individuals who had self- 
tested and were linking for different services according 
to self- test results.
HIVST intervention in study communities (wards)
PSI Zimbabwe identified, recruited and trained CBDs 
from each ward to distribute HIVST kits. Selection of 
CBDs was informed by community leaders, who recom-
mended individuals whom they felt were suitable distrib-
utors based on previous experience of working with HIV 
programmes, community work, literacy levels and good 
standing in the community, hence CBDs were a heter-
ogeneous group with different backgrounds and levels 
of experience. PSI provided CBDs with a 2- day training 
in HIV testing, supporting others to use HIVST kits, 
providing information to promote and support linkage 
to appropriate post- test services, use of data capture tools 
and the study protocol. Each village (smallest subunit of a 
ward that varies in size but typically has about 100 house-
holds) had one or two CBDs depending on size. Over four 
to 4–6 weeks, CBDs conducted door- to- door visits offering 
oral fluid self- test kits to all household members≥16 years 
old (the Ministry of Health- prescribed minimum age for 
consenting to HIV testing). Kits were only given to indi-
viduals providing verbal consent for self- testing. CBDs 
recorded distribution data onto computer tablets. They 
advised clients to seek further HIV services as needed 
from PSI outreach clinics and/or local primary clinics. 
Kit recipients were given a toll- free helpline number that 
they could use as needed.
PSI staff provided outreach clinic services described 
above (Population and Setting) soon after starting and 
completing HIVST distribution, and provided support 
and supervision to CBDs throughout the campaign, 
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including checks for implementation fidelity which were 
done through unannounced spot checks (CBDs were 
informed these would happen during their training).
Study design and modification
The initial protocol was a factorial design23 whereby the 
44 out of a possible 254 wards (clusters) were randomly 
allocated (1:1:1:1) to four arms. HIVST was distributed 
across all arms. All arms included fixed CBD stipends 
of US$50 paid after an anticipated four to 4–6 weeks of 
HIVST distribution and either: (i) conditional incen-
tives for CBDs (US$0.20 for each person who linked to 
post- test services at PSI outreach site), (ii) conditional 
incentives and demand- side (transport assistance) 
incentives for clients confirmed HIV positive to facili-
tate linkage to treatment, (iii) transport assistance for 
clients confirmed HIV positive and (iv) neither condi-
tional incentives for CBDs nor transport assistance 
(figure 1).
The initial primary outcome was uptake of any health 
service at PSI clinics following distribution of self- 
test kits. However, on implementation (Mberengwa 
District), two major problems became apparent: first, 
transport assistance for recently diagnosed HIV patients 
had become standard of care, thus precluding evaluation 
of this intervention. Second, linkage data showed much 
higher than anticipated use of non- PSI clinics.
Hence, in consultation with our Technical Advi-
sory Group (TAG), the demand- side incentive was 
dropped, and primary and secondary outcomes were 
redefined around endline survey data that did not 
require direct capture of clinic use. The six Mberengwa 
district clusters were dropped from analysis, leaving 38 
wards in their original allocation for a two- arm cluster- 
randomised trial comparing fixed stipend only versus 
fixed stipend plus conditional incentives. The fixed 
stipend is standard practice for PSI community- based 
interventions.
The conditional incentive amount ($0.20 per client 
attending PSI clinic services, including non- HIV 
services) was determined through consultation between 
researchers and programme implementers, aiming for 
an amount that was affordable and thus scalable, yet high 
enough to motivate desired behaviour but low enough to 
minimise the risk of unethical behaviour (such as forced 
Figure 1 Trial profile. *The initial design was a 2x2 factorial trial with two interventions: conditional incentives for CBDs and 
bus fare reimbursements to support linkage to care for clients testing HIV positive. However, during implementation in the 
first six clusters (in one District, Mberengwa), transport support for clients testing positive became standard of care, thus 
precluding evaluation of the intervention. We therefore dropped the bus fare reimbursement intervention after consultation with 
the Technical Advisory Group. This left 38 clusters in seven districts with their distributor- incentive allocation intact. **No figures 
provided by one distributor in each arm. CBDs, community- based distributors
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testing, false clients) among CBDs. To give a sense of the 
value, at the time of the study, a loaf of bread cost $0.70–
$0.90 and a local one- way bus ticket cost $0.20–$0.50.
Administration of incentives was based on counting 
appointment cards provided to each HIVST client that 
were redeemed by PSI mobile clinic staff. Client self- 
reports were also accepted from clients who could not 
produce appointment cards but had a convincing account 
of having self- tested, for example, requests for confirma-
tory testing and/or production of used kits. Since CBDs 
operated in defined geographic areas, the residence of 
the client could be used to identify the CBD.
In addition to the trial, we conducted a before- during- 
after time- series analysis of ART initiations in clinic catch-
ment areas receiving and not receiving HIVST, described 
below.
Randomisation and masking
Under the original study design, 44 clusters were 
randomly allocated to one of four arms. Randomisa-
tion was restricted by district and proximity to a health 
facility24 using Stata V.15.1. From more than 7.5 billion 
ways of randomising 44 clusters to four arms, we randomly 
selected 100 000 on which we applied the restriction 
criteria. This produced 32 629 eligible allocations from 
which we randomly selected 1000. During a public rando-
misation ceremony, we randomly selected one of these 
allocations.
Although distributors were not masked to study arm, 
clients receiving HIVST did not know that there were 
differences in the way distributors were paid, and all 
analyses used masked data (study arms were anony-




The primary outcome was the proportion of survey 
participants who self- reported having accessed any clinic 
services from PSI outreach or local clinic visits since the 
start of HIVST kit distribution in their cluster, regardless 
of whether they had self- tested or not. This was assessed 
through response to the question ‘Since about six weeks 
ago (when CBDs came to your area to distribute self- test 
kits), have you been to a clinic or HIV testing facility for 
any service that you wanted for yourself?’. The outcome 
included non- HIV services such as hypertension, diabetes 
screening and family planning services to prevent unin-
tended disclosure of HIV status.
Secondary outcomes were the proportion of survey 
participants self- reporting that they had:
1. Used an HIVST kit (all respondents).
2. Accessed confirmatory testing (for respondents who 
stated having self- tested positive only).
3. Initiated ART (for respondents who stated having self- 
tested positive only).
4. Self- tested HIV- negative and had VMMC (for previous-
ly uncircumcised male respondents only).
Outcome evaluation
Population-based surveys
Six to 8 weeks after completion of HIVST kit distribu-
tion, a population- based survey was conducted in four 
randomly selected National Census Office Enumeration 
Areas (EA) in each cluster. Within each EA, 50% of house-
holds were randomly selected using Open Data Kit,25 and 
all members of selected households aged ≥16 years were 
invited to participate, with written informed consent. 
Questionnaires used Audio Computer Assisted Self Inter-
view (ACASI) on electronic tablets (male/female partic-
ipants listened to male/female voices, respectively) and 
included demographic details; history of HIV testing and 
ART; access to, use and results of self- testing and uptake 
of any health services including confirmatory testing and 
ART following kit distribution.
The survey was conducted at population level (rather 
than restricted to individuals who received HIVST kits) 
because we wanted to determine HIVST uptake and 
population level impact of the interventions.
ART clinic data extraction for before–during–after time series 
analysis
Catchment areas (defined and published at health facil-
ities) of all public sector facilities providing ART in each 
district were mapped in relation to wards of both trial arms 
and categorised into clinics with and without catchment- 
area HIVST distribution. Numbers of ART initiations per 
month were extracted from clinic registers for the period 
6 months before HIVST distribution, during distribution, 
and 3 months following completion of distribution. For 
clinics without catchment- area HIVST, we matched the 
before–during timepoints to those of the closest trial 
ward.
Time series evaluations can be affected by concurrent 
campaigns/initiatives, but during the trial, PSI were 
the only organisation partnering Ministry of Health to 
provide HIV testing services in the selected study districts 
(and were the only provider of HIVST in the country).
Before–during–after study
Differences in ART initiation rates for public sector 
health facilities were defined by time period (before, 
during and after) of HIVST distribution, using preinter-
vention initiation rates as the baseline for each clinic, and 
comparing during–after time trends between facilities 
with and without catchment- area HIVST distribution.
Statistical methods
Study power
Following protocol amendment to the two- arm design, 
the study power was recalculated, having initially been 
based on differences in demand for PSI outreach 
services. Using standard methodology,26 and assuming 
200 postintervention survey participants per cluster, an 
intercluster coefficient of variation (k) of 0.3, and 10% 
uptake of any clinic service (as informed by a previous 
survey) among postintervention survey participants in 
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the least effective arm, then 38 clusters would provide 
>90% power to detect a 50% difference between arms, 
from an assumed 10%–15%.
Analysis of population-based survey data
The statistical analysis plan was finalised for the two- arm 
(modified intention- to- treat) trial before data collection 
ended. Analysis used Stata V.15.1.27 We conducted logistic 
regression of individual- level data, with random effects 
adjustment to account for the cluster26 to estimate preva-
lence ratios and differences by arm, and their associated 
95% CI.28 A permutation test incorporating the restric-
tion criteria used for randomisation was used to estimate 
the primary outcome p- value.
The primary and secondary analyses were adjusted 
for imbalance by arm in a priori variables, with educa-
tional attainment, household food insecurity and mental 
distress meeting these criteria. Household food inse-
curity was defined by ≥2 affirmative responses to three 
questions, one from each domain of the Household 
Food Insecurity Access Scale.29 Risk of mental distress was 
defined by a score of ≥9 on the locally validated Shona 
Symptom Questionnaire.30
Sub- group analyses used data stratified by sex, age, 
food insecurity and mental distress. Sensitivity analyses, 
accounting for clustering at both the ward and house-
hold levels are shown in online supplemental appendix 
2.
Analysis of ART clinic data
Generalised estimation equations were used to analyse 
relationships between ART initiation and campaign 
period, and to test for differences between clinics with 
and without catchment- area HIVST distribution, and 
between trial arms. We fitted separate models assessing 
rate differences and rate ratios. For both models, we 
assumed ART initiations were Poisson distributed. In 
both analyses, we adjusted for district (fixed effect), 
observation days (offset), preintervention clinic testing 
rates (average number of post- test counselling sessions 
per month, modelled as quadratic) and calendar month 
(fixed effect).
Ethical considerations and governance
As the conditional incentive intervention carried minimal 
risk to participants, no interim analyses were planned. An 
independent TAG met every 6 months to review progress.
Patient and public involvement
Before the trial, we conducted formative research 
including qualitative studies and discrete choice exper-
iments where we obtained communities’ preferences for 
door- to- door distribution of HIV self- tests.4 31 We used 
these findings to refine the HIVST distribution strategy. 
During the trial, as part of community entry activities, the 
study team met with community leaders in each ward to 
seek their consent for involvement of their communities 
and their guidance in the selection of CBDs. At the end 
of the study, community meetings were held to discuss 
research findings and get views on what worked well/less 
well during the intervention.
Role of the funding source
The funder did not influence the study design, protocol 
writing process, implementation decisions, data analysis 
and data interpretation. The corresponding author has 
full access to data.
RESULTS
Between August 2016 and August 2017, 445 CBDs in the 
conditional incentive arm and 447 CBDs in the no incen-
tive arm distributed a mean of 88 (CI: 85 to 92) and 93 
(CI: 89 to 96) kits each, respectively. The total distrib-
uted per arm was 39 205 and 41 173 (figure 1). Popula-
tions sizes were similar by arms, with harmonic means of 
3993 (CI: 2881 to 6501) and 4796 (CI: 4020 to 5944) in 
HIVST and non- HIVST communities, respectively (based 
on 2012 census data). Distribution was carried out over 
19 days (range 19–25 days) per cluster, with a median of 
2313 (IQR: 1403–2521) kits distributed per cluster in the 
conditional incentive arm and 2071 (1646–2616) in the 
no incentives arm. In total, 171 (38.4%) CBDs in condi-
tional incentive arm were given conditional incentives, 
with incentive amounts ranging from $0.20 to $6.00 
(median $0.80), corresponding to 1–30 clients linked 
per CBD.
The postintervention survey included 7146 participants 
from 3813 households, with a response rate of 83.8% in 
the conditional incentive arm and 83.0% in the no incen-
tive arm. Participant characteristics were largely compa-
rable between arms (table 1), although small imbalances 
by arm in food insecurity, education and mental distress 
were adjusted for in subsequent analyses.
Overall, 6335 (88.7%) of participants had ever tested 
for HIV (table 2), and 5838 (81.7%) had ever heard of 
HIVST. Of note, 4039 (56.5%) of those who had heard 
of HIVST had taken a self- test kit during HIVST distribu-
tion, and 3593 (89.0% of kit recipients) reported having 
self- tested. The overall population uptake of HIVST was 
50.3% (3593/7146). Uptake varied relatively little by arm, 
age or sex, with 46.2% of young people (age 16–25 years) 
and 46.5% of men reporting having self- tested. Among 
self- testers, 36.3% (1305/3593) reported that HIVST was 
their first ever HIV test; this represented 18.3% of the 
overall sample.
Effect of conditional incentives
Uptake of HIVST
There were 1770 (47.9%) and 1823 (52.9%) participants 
who reported self- testing in the conditional incentives 
and no incentives arms, respectively, giving an adjusted 
prevalence ratio (aPR) 0.91 (95%CI: 0.80 to 1.02).
Uptake of post-HIVST distribution services (primary outcome)
We found no evidence of a difference in uptake of post- 
HIVST services by arm with 1062 (28.7%) and 1075 
(31.2%) clients in conditional incentive and no incentive 
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Table 1 Characteristics of respondents in household surveys
  
Conditional incentive No incentive Total
No. No. No.
Clusters (no.) 19 19 38
Households (no.) 1966 1847 3813
Respondents (no.) 3698 3448 7146
Mean respondents per cluster (geometric) 182.49 177.72 180.09
  Mean SD Mean SD Mean SD
Household characteristics
  Adult respondents per household (mean/SD) 1.73 0.89 1.71 0.92 1.72 0.9
  Adolescent respondents per household (mean/SD) 0.15 0.4 0.16 0.39 0.15 0.39
No. % No. % No. %
Household wealth quintile (no./%)
  Poorest 505 25.69 529 28.64 1034 27.12
  Second 312 15.87 294 15.92 606 15.89
  Middle 419 21.31 336 18.19 755 19.8
  Fourth 373 18.97 347 18.79 720 18.88
  Least poor 357 18.16 341 18.46 698 18.31
Household food insecurity (no./%) 1190 60.53 1103 59.72 2293 60.14
  Mean SD Mean SD Mean SD
Individual characteristics
  Age (mean/SD) 39.2 18.4 38.8 18 39 18.2
No. % No. % No. %
Age in groups
  16–19 years 591 16 513 14.9 1104 15.5
  20–29 years 799 21.6 778 22.6 1577 22.1
  30–39 years 718 19.4 706 20.5 1424 20
  40–49 years 532 14.4 528 15.3 1060 14.9
  50–59 years 428 11.6 360 10.5 788 11
  60 years and older 625 16.9 558 16.2 1183 16.6
Male (no./%) 1414 38.2 1353 39.2 2767 38.7
Marital status (no./%)
  Married or living as married 2169 58.7 2071 60.1 4240 59.3
  Never married 853 23.1 764 22.2 1617 22.6
  Widowed/separated/divorced 676 18.3 613 17.8 1289 18
Highest level of education (no./%)
  None or primary only 1664 45 1428 41.4 3092 43.3
  Some secondary 1008 27.3 903 26.2 1911 26.7
  O- levels complete 856 23.1 942 27.3 1798 25.2
  A- level and higher 170 4.6 175 5.1 345 4.8
Able to read a newspaper or letter (no./%) 570 15.4 583 16.9 1153 16.1
Religion (no./%)
  Apostolic 1230 33.3 1220 35.4 2450 34.3
  Other Christian denomination 1115 30.1 1128 32.8 2243 31.4
  Other, including no religion 1353 36.6 1100 31.9 2453 34.3
Receives regular salary (no./%) 570 15.4 583 16.9 1153 16.1
Continued
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arm, respectively, linked to any service (aPR=0.94; 95% CI: 
0.86 to 1.03, permutation test p=0.13; table 3). The 
majority of participants who linked (1768/2137; 82.7%) 
visited the local clinic/hospital. The most commonly 
sought post- test services from the local clinic/hospital 
(multiple responses possible) were HIV testing and 
counselling (38.6%), treatment for an ailment (16.7%), 
routine clinic visit or prescription refill (12.2%), HIV 
care—CD4 cell count (12.1%) and family planning 
services (11.0%). Subgroup analysis showed no evidence 
of a difference in linkage to post- test services by arm, by 
gender, age, food insecurity or mental distress (online 
supplemental appendix 3). The cluster coefficient of 
variation, k, for uptake of post- test services was 0.05.
Other outcomes
We did not find evidence of a difference by arm for our 
secondary outcomes of linkage to PSI outreach services 
(table 3). The preset analyses of confirmatory testing and 
uptake of ART for participants with reactive self- tests were 
dominated by retesting while already on ART (table 3), 
which was not the intention of this intervention. As such, 
we also present a post- hoc analysis excluding respond-
ents who reported they were already on ART at the time 
of HIVST (table 3). This provides some evidence that 
individuals with newly diagnosed HIV were more likely 
to have attended for confirmatory testing in the condi-
tional incentives arm (23/33, 75.8%) compared with the 
no incentive arm (20/40, 50.0%): aPR 1.59; 95% CI 1.05 
to 2.39.
Effect of HIVST on ART clinic initiations
To determine the effect of HIVST on ART initiations, 
we extracted data from all 164 health facilities that 
provided ART in the study districts. Of these, 40 facil-
ities served the 38 HIVST communities and recorded 
3138 ART initiations, while 124 facilities were outside 
the catchment- area for HIVST distribution and reported 
9670 ART initiations. Our data show that the average 
number of ART initiations per clinic day preinterven-
tion was similar between HIVST and non- HIVST health 
facilities. During the period of HIVST distribution, 
there was a difference in rate of ART initiations between 
HIVST distribution and non- HIVST areas; this differ-
ence disappeared after completion of HIVST distribu-
tion. Online supplemental appendix 4A summarises 
the number of ART initiations per month during the 
three periods before, during and after HIVST distribu-
tion in HIVST and non- HIVST communities: in HIVST 
communities, the number of ART initiations increased 
during the distribution period from 7.31 to 9.59 initia-
tions per month, then decreased thereafter to 6.53 initi-
ations per month.
Figure 2 illustrates the change in ART initiation rates 
over time and interaction with HIVST, with the increase 
in ART initiation rates in HIVST communities corre-
sponding to an adjusted ART initiation rate ratio of 1.27 
(95% CI: 1.13 to 1.42). Details are given in online supple-
mental appendix 4B. Once HIVST distribution ended, 
the adjusted initiation rate ratio was 1.02 (95% CI: 0.88 to 
1.18) compared with the preintervention period. There 
No. % No. % No. %
SSQ*>=9 (no./%) 1599 43.2 1622 47 3221 45.1
Ever tested for HIV (no./%) 3236 87.5 3099 89.9 6335 88.7
Self- reported HIV+ (no./%) 450 12.2 377 10.9 827 11.6




Table 2 Coverage of self- testing after distribution
Characteristic Conditional incentives No incentives Total
Respondents—number 3698 3448 7146
Ever tested for HIV 3236/3698 (87.5%) 3099/3448 (89.9%) 6335/7146 (88.7%)
Ever heard of HIV self- testing 2962/3698 (80.1%) 2876/3448 (83.4%) 5838/7146 (81.7%)
Received kit during intervention 1983/3698 (53.6%) 2056/3448 (59.6%) 4039/7146 (56.5%)
Used kit to self- test 1770/3698 (47.9%) 1823/3448 (52.9%) 3593/7146 (50.3%)
% First- time testers 642/3698 (17.4%) 663/3698 (19.2%) 1305/7146 (18.3%)
Overall coverage of self- testing 1770/3698 (47.9%) 1823/3448 (52.9%) 3593/7146 (50.3%)
Coverage among men 628/1414 (44.4%) 658/1353 (48.6%) 1286/2767 (46.5%)
Coverage among aged <25 years 463/1037 (44.7%) 456/952 (47.9%) 919/1989 (46.2%)
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was no difference in ART initiation by trial arm post- 
HIVST distribution (data not shown).
DISCUSSION
In this pragmatic cluster- randomised trial, we found 
that community- based HIVST campaigns achieved high 
uptake of testing across both arms, including groups 
with historically low testing rates (men, young people) 
and those who had not tested previously. Using a sepa-
rate quasi- experimental design, we showed that HIVST 
campaigns in both arms were associated with a 27% 
relative increase in ART initiation rates at nearby public 
health facilities, with return to pre- HIVST rates as soon as 
the campaign was over. There was, however, no evidence 
of additional benefit from providing kit distributors with 
a small linkage incentive (US$0.20 per client linked) on 
top of a fixed stipend, with no evidence of a difference 
between arms on uptake of post- test services including 
ART or on HIVST uptake. Uptake of confirmatory testing 
was higher for newly diagnosed HIV- positive participants 
in the conditional incentive arm, but this finding was 
based on small numbers and was a post- hoc modification 
to the planned analysis to exclude clients who were using 
HIVST to re- test while on ART.
Our results add to the growing body of evidence 
showing that HIVST can increase uptake of HIV testing.15 
Following HIVST distribution, 88.7% of participants 
surveyed reported ever testing for HIV, compared with 
75% in the nationally representative Zimbabwe Public 
Health Impact Assessment conducted in the same year.12 
These data suggest that campaign style HIVST distribu-
tion can bring about a step change in knowledge of HIV 
status, with good uptake by men, young people and a 
substantial proportion being first- time testers. Of note, 
we found an increase in ART initiation immediately after 
commencement of HIVST distribution, with rates going 
back to previous levels after distribution stopped, showing 
the value of self- testing in achieving timely linkage.
Studies of community- based provider testing have 
shown longer times to linkage than suggested by our 
ART clinic- level data,32 33 for instance in the HIV Preven-
tion Trials Network 071 trial (known as POPART) in 
Zambia and South Africa, the median time to linkage was 
6 months. Data from our survey, conducted just 6 weeks 
after the HIVST campaign data, add support to more 
rapid linkage with most previously undiagnosed self- 
testers with reactive results having already confirmed 
them. It is plausible that reactive (positive) self- tests may 
tend to prompt more rapid action than reactive provider- 
tests, given the additional uncertainties regarding the 
result and likely desire for experienced in- person post- 
test counselling. Not only are reactive self- tests prelimi-
nary (unconfirmed by a second or third test kit), but 
self- testers acknowledge their own inexperience as a 
motivator for clinic confirmation when they get unex-
pected results.34
A small conditional incentive of US$0.20 per person 
taking up post- test services did not increase linkage 
overall although confirmatory testing of newly diag-
nosed HIV- positive HIVST clients appeared to have been 
increased. Existing literature has shown the effectiveness 
of demand- side incentives on engagement along the HIV 
cascade, including increasing linkage to HIV care and 
prevention following self- testing among male partners 
of women attending antenatal care clinics in Malawi.19 
Importantly, the Malawi trial showed a dose- effect with 
US$10 more effective than US$3 in prompting post- 
HIVST clinic attendance.19 In contrast, uptake of HIVST 
by male partners, which was already 93% in the no- in-
centive arm—implying strong inherent motivation, was 
unaffected by incentivisation.19 Motivation was high in 
both arms of the current trial, with CBDs reporting pride 
in delivering an important and novel intervention to 
their community.35 Motivation was also potentially driven 
by the $50 base amount. We could not test a range of 
amounts for the conditional incentive due to time pres-
sure and acknowledge that the amount may simply have 
been too low. We were constrained to test a small amount 
that was potentially scalable but with low risk of unin-
tended consequences.
Measuring linkage is already challenging for standard 
provider- delivered HIV testing, but becomes more so 
with self- testing with loss of provider- control over the 
test results.36 Attempts to track cohorts of HIV self- testers 
and link individual HIVST clients to confirmatory testing 
and ART initiation events, as occurs for monitoring 
standard HIV testing services, may be futile. Even using 
more approximate triangulation approaches looking at 
initiation rates at health facilities may be undermined by 
clients failing to disclose previous testing episodes and 
results. Additionally, some clients may opt to initiate 
treatment in a different location from where they initially 
tested positive to maintain confidentiality. The lack of 
Figure 2 Trends in ART initiation rates before, during and 
after the HIVST campaign period.
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national unique patient identifiers which can be used to 
track individuals across facilities coupled with poor pene-
tration of electronic medical record systems in many 
African settings adds to this challenge. Despite its limita-
tion, the approach used here to infer linkage to care 
following HIVST through a time- series analysis, provides 
an effective, low cost alternative to evaluating the impact 
of HIVST, circumventing the difficulties of measuring 
linkage more directly, and is one that other programmes 
could consider if using similar high intensity campaigns 
aimed at high coverage.
The major strength of this study was the large- scale 
implementation of community- based HIVST, providing 
evidence on feasibility, coverage and linkage. The 
accompanying time- trend analysis showing increased 
clinic- level ART initiations associated with HIVST adds 
powerful support for HIVST- related health outcomes 
using methods that bypass the need for cohort tracking 
despite also showing no difference between incentive 
trial arms. PSI was the sole HIV testing partner operating 
in the study districts, allowing us to confidently exclude 
non- study interventions during the HIVST campaign 
period.
Limitations include potential bias from trial outcomes 
based on self- report, although we used ACASI to mini-
mise this risk.37 The trial deviated from the original 
design (see Methods section), dropping one of the two 
planned interventions (demand- side incentives) and 
redefining the way that the primary outcome was to be 
captured, which necessitated removal of one district (six 
clusters) from analysis postrandomisation. As rando-
misation was restricted by district, we retained balance 
between arms in the remaining clusters. People already 
on ART using HIVST to retest, which is common for a 
variety of reasons,8 38 39 outnumbered new HIV diagnoses 
in our endline survey necessitating post- hoc adaptation 
of confirmatory testing outcome. Retesting on ART has 
become more problematic for evaluation of routine 
HIV testing services, regionally, as countries approach 
90-90-90 targets, and should be discouraged as far as 
possible. We acknowledge that our conclusions regarding 
conditional incentives would have been more robust had 
we been able to include prior dose- ranging studies. For 
the difference- in- differences analysis, clinic catchment 
areas were larger than HIVST clusters and not all newly 
diagnosed PLHIV will choose their local clinic for HIV 
services: one explanation for the smaller peak seen for 
designated non- HIVST clinics during HIVST distribu-
tion (figure 2). As such, we may have underestimated the 
effect of HIVST campaigns on demand for ART.
In summary, community- based HIVST campaigns 
achieved a step change in uptake of HIV testing, 
including among men and young people who typically 
have poor testing uptake. HIVST was accompanied by 
a significant increase in clinic- based ART initiations 
during the campaign period. Delivery of HIVST by 
briefly trained community members was feasible, but 
a conditional financial incentive added little to their 
performance over a fixed stipend to distribute this novel 
technology, suggesting either high levels of inherent non- 
monetary motivators, or a subeffective incentive amount 
or a combination of these two. Given our post- hoc anal-
ysis showing higher linkage to confirmatory testing for 
newly diagnosed HIV- positive clients in the conditional 
incentive arm, future research should aim to optimise 
the nature and size of incentives to increase uptake and 
linkage while weighing the benefits and costs as high-
lighted in WHO guidance.40
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